Clinical Trial Search

Primary: Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12 — 32; 31; 6; 26 Participants — p=<.0001

Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 — 11.0; 57.0 percentage of participants…

Primary: Success of Investigator's Global Assessment (IGA) — 3; 7 Participants

Primary: Number of Participants With Adverse Events — 161; 149; 140; 14 participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI) — 83.3; 85.7; 85.2; 92.3 percentage of…

Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 — 11.5; 33.1 percentage of participants — p=<0.0001

Primary: Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants — 0; 0; 0 Participants

Primary: Change From Screening in Serum Albumin Levels at Week 4 — -1.0 gram per liter (g/L)

Primary: Cmax of Calcitriol Plasma Level — 120.7 pg/mL

Primary: Number and Percentage of Participants With PASI 75 Response — 39; 39 Participants

Primary: Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 — 32.4; 43.6; 57.9 percentage of participants — p=0.027

Primary: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab) — 25; 88.7 percentage of participants — p=<0.001

Primary: Plasma Concentration of ARQ-151 Cream 0.3% — 3.15; 1.68 ng/mL

Primary: Trough Plasma Levels (Ctrough) of Calcitriol — 65.04; 62.53; 61.87; 61.46 Picograms Per Millilitre (pg/mL)

Primary: Percentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12 — 77.3 percentage of participants

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…

Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale

Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495

Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment — -60.8; -54.2 percentage of…

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…

Primary: Number of Subjects With Adverse Events (AEs) — 8; 4; 1; 1 Participants

Primary: Adverse Drug Reactions (ADRs) — 2; 1; 1; 1 Number of adverse drug reactions

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change